V CompBrief BY VELARION

General Counsel and Corporate Secretary · Lineage Cell Therapeutics, Inc. (LCTX)

George Samuel III

FY2025 is the first fiscal year CompBrief holds for George Samuel III as a named executive officer of Lineage Cell Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$978,225

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

George Samuel III compensation by year

Lineage Cell Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Lineage Cell Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$448,500
Bonus$0
Stock awards$0
Option awards$287,925
Non-equity incentive$224,300
Pension and deferred compensation$0
All other$17,500
Total$978,225

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lineage Cell Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191556, and prior-year filings. Open the filing on EDGAR.

Lineage Cell Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Brian CulleyChief Executive Officer$2,111,170
Jill HoweChief Financial Officer$1,005,925
George Samuel III · this pageGeneral Counsel and Corporate Secretary$978,225

The full Lineage Cell Therapeutics compensation record

free company brief
Lineage Cell Therapeutics, Inc. (LCTX) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within Lineage Cell Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Lineage Cell Therapeutics's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $1,500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lineage Cell Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy